Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Open AARD dashboard ↗BridgeBio Pharma, Inc. Common Stock
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Open BBIO dashboard ↗